← Back to all trials
Not Yet Recruiting
NCT07718867
Point-of-care Capillary HbA1c Testing for Type 2 Diabetes Screening Among At-risk Individuals in Rural Dali, China
Conditions: Type 2 Diabetes, Pre-diabetes
Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: NA
Enrollment: 720
Sponsor: The University of Hong Kong
Location: The First People's Hospital of Dali Dali Yunnan
Summary
This project aims to compare Point-of-care capillary HbA1c (POC-cHbA1c) testing and fingerstick random blood glucose (RBG) testing in terms of type 2 diabetes detection rate and cost-effectiveness, in order to optimise current screening strategies for rural populations at high risk of diabetes in rural Dali, China, and to improve treatment adherence and self-management among people with diabetes.
Eligibility Criteria
Inclusion Criteria:
* Aged 18 years or above;
* Permanent residents of Dali City who have lived locally for at least six consecutive months;
* Registered as rural residents;
* No known history of diabetes;
* Meet at least one of the high-risk criteria for T2DM specified in the Chinese Guidelines for the Prevention and Treatment of Diabetes issued by the Chinese Diabetes Society;
* Able to understand the study information and provide written informed consent.
Exclusion Criteria:
* Known history of T2DM or currently receiving glucose-lowering treatment;
* HbA1c testing with a clear result within the past three months, or completion of standardised diabetes screening within the past six months;
* Pregnant or breastfeeding at the time of recruitment;
* Active thyroid disease or other active endocrine disorders at recruitment, such as Cushing's syndrome or acromegaly;
* Known haemoglobinopathy, severe anaemia, recent acute blood loss, or history of blood transfusion or blood donation within the past three months;
* Currently receiving treatment that may substantially affect interpretation of HbA1c, such as erythropoietin therapy or recent high-dose iron therapy.
Source: ClinicalTrials.gov (NCT07718867). StuddyBuddy aggregates publicly available trial information.